Valeant Pharmaceuticals International (NYSE:VRX) traded today at a new 52-week high of $67.98. This new high was reached on below average trading volume as 576,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares.
Valeant Pharmaceuticals International share prices have moved between a 52-week high of $67.98 and a 52-week low of $42.47 and are now trading 59% above that low price at $67.71 per share. The 200-day and 50-day moving averages have moved 0.43% higher and 1.50% higher over the past week, respectively.
Valeant Pharmaceuticals International has overhead space with shares priced $67.71, or 6.1% below the average consensus analyst price target of $72.13. The stock should find initial support at its 50-day moving average (MA) of $61.45 and further support at its 200-day MA of $54.13.
Valeant Pharmaceuticals International is a research-based, specialty pharmaceutical company that markets its products worldwide. The Company discovers, develops, manufactures, and markets a range of pharmaceutical products, focusing on products in the areas of infectious disease, neurology, and dermatology.